For Immediate Release
ADESA and EMKAY Raise $50,000 for JDRF
CARMEL, Ind.—ADESA, a business unit of KAR Auction Services (NYSE: KAR), today announced that ADESA auctions and EMKAY have together raised more than $50,000 in 2016 to support the research efforts of JDRF, the world leader in funding type 1 diabetes (T1D) research.
Between March 1 and November 30, EMKAY and ADESA each made a $10 donation for every EMKAY vehicle purchased at 20 participating ADESA auction locations. The total raised during the nine-month campaign was $52,460.
Since EMKAY and ADESA formed a fundraising partnership for this cause five years ago, the two companies have raised more than $210,000 for JDRF.
“JDRF is singularly focused on the worldwide effort to end type 1 diabetes, and ADESA is proud to work closely with EMKAY each year in this important fundraising effort,” said ADESA President and CEO Stéphane St-Hilaire. “Almost everyone has a friend or family member fighting this disease, and we’re committed to doing our part to help find a cure for something that affects so many people.”
ADESA offers a full range of auction, reconditioning, logistical and other vehicle-related services to meet the remarketing needs of both its institutional and dealer customers. The company handles virtually every stage of the used-vehicle lifecycle through its related subsidiaries of PAR North America, RDN, AutoVIN and CarsArrive. Remarketing services include a variety of activities designed to transfer used vehicles between professional sellers and buyers.
ADESA hosts weekly sales at its 78 auction locations across the United States, Canada and Mexico. The company also builds and manages online sale platforms for many major vehicle manufacturers. The company’s online auction venues include ADESA LiveBlock, which simulcasts vehicles worldwide; and ADESA DealerBlock, which offers two ways to buy: bid-now sales events or buy-now pricing 24/7. ADESA is part of the KAR Auction Services group of companies. Visit ADESA.com for details.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. As the largest charitable supporter of T1D research, JDRF has invested more than $2 billion in research over the past 45 years and is currently funding 50 human clinical trials of potential T1D therapies. For more information, please visit www.jdrf.org.